Ulcerative Colitis - Pipeline Review, H1 2020

April 2020 | 671 pages | ID: U44188EFA0EEN
Global Markets Direct

Abstracts

Ulcerative Colitis - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis - Pipeline Review, H1 2020, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape.

Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer, depression, and severe dehydration. Common symptoms of ulcerative colitis include rectal bleeding, abdominal pain, and diarrhea. Treatment options for ulcerative colitis include surgery (removal of colon) or drug therapy with aminoasylates (ASA), immunomodulators, and corticosteroids.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ulcerative Colitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Ulcerative Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ulcerative Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 19, 53, 32, 2, 76 and 14 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 12 molecules, respectively.

Ulcerative Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Ulcerative Colitis (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Ulcerative Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Ulcerative Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Ulcerative Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Ulcerative Colitis (Gastrointestinal)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Ulcerative Colitis (Gastrointestinal).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Ulcerative Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Ulcerative Colitis - Overview
Ulcerative Colitis - Therapeutics Development
Ulcerative Colitis - Therapeutics Assessment
Ulcerative Colitis - Companies Involved in Therapeutics Development
Ulcerative Colitis - Drug Profiles
Ulcerative Colitis - Dormant Projects
Ulcerative Colitis - Discontinued Products
Ulcerative Colitis - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Ulcerative Colitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..7), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Ulcerative Colitis - Pipeline by 4D Pharma Plc, H1 2020
Ulcerative Colitis - Pipeline by AbbVie Inc, H1 2020
Ulcerative Colitis - Pipeline by AbGenomics International Inc, H1 2020
Ulcerative Colitis - Pipeline by Abivax SA, H1 2020
Ulcerative Colitis - Pipeline by Aclaris Therapeutics Inc, H1 2020
Ulcerative Colitis - Pipeline by Affilogic SAS, H1 2020
Ulcerative Colitis - Pipeline by Akebia Therapeutics Inc, H1 2020
Ulcerative Colitis - Pipeline by Akeso Biopharma Inc, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Ulcerative Colitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

4D Pharma Plc
AbbVie Inc
AbGenomics International Inc
Abivax SA
Aclaris Therapeutics Inc
Affilogic SAS
Akebia Therapeutics Inc
Akeso Biopharma Inc
Algernon Pharmaceuticals Inc
Alivio Therapeutics Inc
Allergan Plc
Alpha Cancer Technologies Inc
Alvotech ehf
Am-Pharma BV
Amgen Inc
Antibe Therapeutics Inc
Apidel SA
Applied Molecular Transport LLC
Arena Pharmaceuticals Inc
Artelo Biosciences Inc
AsiaBiome
Asta Pharmaceuticals Co Ltd
Atlantic Bio Sci LLC
Atlantic Healthcare Plc
Avexegen Therapeutics Inc
Axim Biotechnologies Inc
Bilix Co Ltd
BioXpress Therapeutics SA
Boehringer Ingelheim International GmbH
Bridge Biotherapeutics Inc
Bristol-Myers Squibb Co
Cellix Bio Pvt Ltd
Celltrion Inc
Chain Biotechnology Ltd
ChemoCentryx Inc
Chong Kun Dang Pharmaceutical Corp
Circle33 LLC
Cloud Pharmaceuticals Inc
Cosmo Pharmaceuticals NV
Cristcot HCA LLC
CrystalGenomics Inc
Cureveda LLC
Cytocom Inc
Dadang & BIO Co Ltd
DeNovX LLC
Devonian Health Group Inc
DM Bio Ltd
DNX Biopharmaceuticals Inc
Dr. August Wolff GmbH & Co KG Arzneimittel
EA Pharma Co Ltd
Eli Lilly and Co
Enceladus Pharmaceuticals BV
enGene Inc
Exeliom Biosciences SAS
F. Hoffmann-La Roche Ltd
Ferring International Center SA
Finch Therapeutics Group
First Wave Bio Inc
FYB202 GmbH & Co KG
Galapagos NV
Genentech Inc
Gilead Sciences Inc
GlaxoSmithKline Plc
GLW Pharma
Gossamer Bio Inc
Guangzhou Magpie Pharmaceutical Co Ltd
Hefei Cosource Pharmaceutical Inc
Holy Stone Healthcare Co Ltd
Ichnos Sciences Inc
Iltoo Pharma
Immunic Inc
Impetis Biosciences Ltd
Inception Sciences Inc
InDex Pharmaceuticals Holding AB
Innovate Biopharmaceuticals Inc
Innovation Pharmaceuticals Inc
Innovent Biologics Inc
Innovimmune Biotherapeutics Inc
InSight Biopharmaceuticals Ltd
Intact Therapeutics
Intas Pharmaceuticals Ltd
Intract Pharma Ltd
Istesso Ltd
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Kaken Pharmaceutical Co Ltd
Kalytera Therapeutics Inc
Kintai Therapeutics Inc
Koutif Therapeutics LLC
Kyowa Kirin Co Ltd
Landos Biopharma Inc
LG Chem Ltd
LIPID THERAPEUTICS GmbH
LTT Bio-Pharma Co Ltd
MAKScientific LLC
Metacrine Inc
Microbiotica Ltd
Mitsubishi Tanabe Pharma Corp
Morphic Holding Inc
NeuClone Pty Ltd
Nichi-Iko Pharmaceutical Co Ltd
Novartis AG
Nubiyota LLC
Numedii Inc
Nyrada Inc
Oncodesign SA
Oncostellae SL
OSE Immunotherapeutics
Ovamed GmbH
Palatin Technologies Inc
Palo BioFarma SL
Pandion Therapeutics Inc
PanTheryx Inc
Paradigm Biopharmaceuticals Ltd
Pfizer Inc
Pharmapraxis
Pharmaxis Ltd
PNB Vesper Life Science Pvt Ltd
Praeventix LLC
Protab Ltd
Protagonist Therapeutics Inc
Protalix BioTherapeutics Inc
Provention Bio Inc
Qu Biologics Inc
Re-Pharm Ltd
Rebiotix Inc
Regentys Corp
ReveraGen BioPharma Inc
RhemaStem SRLS
Salix Pharmaceuticals Ltd
Saniona AB
Sareum Holdings Plc
Semorex Technologies Ltd
Seres Therapeutics Inc
Servatus Ltd
Shaperon Inc
Siam Bioscience Co Ltd
StemRIM Inc
sterna biologicals Gmbh & Co KG
Sublimity Therapeutics HoldCo Ltd
Suzhou Connect Biopharmaceuticals Ltd
Swedish Orphan Biovitrum AB
Synedgen Inc
Synlogic Inc
Takeda Pharmaceutical Co Ltd
Tarus Therapeutics Inc
TheraSource LLC
Theravance Biopharma Inc
Thetis Pharmaceuticals LLC
Tianjin Hemay Pharmaceutical Co Ltd
Tillotts Pharma AG
TopiVert Ltd
Torrent Pharmaceuticals Ltd
Ventria Bioscience
Vivreon Biosciences LLC
Voronoi